Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Neurologix, Inc.
(OP:
NRGXQ
)
0.0012
USD
+0.0001 (+9.09%)
Official Closing Price
/ Updated:
8:10 PM EDT, May 22, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
1,500
Open
0.0012
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0011
Today's Range
0.0012 - 0.0012
52wk Range
0.0010 - 0.0100
Shares Outstanding
27,997,701
Dividend Yield
N/A
Top News
More News
Neurologix, Inc. (OTC:NRGX) Crashed Down Hard
November 02, 2011
After a number of price hesitations, Neurologix, Inc. (OTC:NRGX) crashed down hard. Yesterday, the stock lost 35.23% on the market, while its traded volume jumped over 448 thousand shares. Historical...
Read More
category
Stocks
from
Hotstocked.com articles
Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
September 20, 2011
- Andrew I. Koven Also Joins Neurologix as Company President and Chief Administrative Officer -
Read More
from
PR Newswire
More News
Read More
Neurologix Announces Second Quarter 2011 Financial Results
August 11, 2011
from
PR Newswire
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
June 08, 2011
from
PR Newswire
Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinson's Disease at International Neuromodulation Society 10th World Congress
May 26, 2011
from
PR Newswire
Neurologix Announces First Quarter 2011 Financial Results
May 13, 2011
from
PR Newswire
Neurologix Announces Year End 2010 Results
March 25, 2011
from
PR Newswire
UPDATE 1-Gene therapy shows promise for Parkinson's
March 16, 2011
category
companyNews
from
Reuters: Company News
Novel Gene Therapy Agent NLX-P101 Effective in Treating Parkinson's Disease in Phase 2 Trial
March 16, 2011
from
PR Newswire
Neurologix Completes Additional $7 Million Financing
December 06, 2010
from
PR Newswire
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here